Publication Name	World Journal of Hepatology
Manuscript ID	16521
Country	Romania

Received	2015-01-21 08:13
Peer-Review Started	2015-01-21 16:23
To Make the First Decision	2015-02-07 14:56
Return for Revision	2015-02-10 16:47
Revised	2015-02-21 01:45
Second Decision	2015-04-01 15:32
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-04-14 16:21
Articles in Press	2015-04-14 16:21
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-06-26 09:01
Publish the Manuscript Online	2015-07-24 19:52

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Voriconazole and the liver
Manuscript Source	Invited Manuscript
All Author List	Romeo-Gabriel Mihăilă
Funding Agency and Grant Number
Corresponding Author	Romeo-Gabriel Mihăilă, MD, PhD, Faculty of Medicine, Lucian Blaga University of Sibiu, Str Lucian Blaga, 2A, 550169 Sibiu, Romania. romeomihaila@yahoo.com
Key Words	CYP2C19; Pharmacokinetics; Liver toxicity; Therapeutic drug monitoring; Voriconazole
Core Tip	Voriconazole is an azole useful for the prophylaxis and the treatment of aspergillosis and other fungal infections in immunosuppressed subjects. Its administration in therapeutic doses lead to extremely varied serum levels from patient to patient and even to the same patient. It is recommended to maintain the serum concentrations of voriconazole between 1.5 and 4 μg/mL. At lower values its efficacy decreases and at higher values the risk of neurological toxicity increases. Even at these concentrations it is not excluded the possible appearance of a variety of toxic effects, including on the liver, manifested by cholestasis, hepato-cytolisis, or their combination.
Publish Date	2015-07-24 19:52
Citation	Mihăilă RG. Voriconazole and the liver. World J Hepatol 2015; 7(14): 1828-1833
URL	http://www.wjgnet.com/1948-5182/full/v7/i14/1828.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i14.1828

Full Article (PDF)	WJH-7-1828.pdf
Full Article (Word)	WJH-7-1828.doc
Manuscript File	16521-Review.doc
Answering Reviewers	16521-Answering reviewers.pdf
Audio Core Tip	16521-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	16521-Conflict-of-interest statement.pdf
Copyright License Agreement	16521-Copyright assignment.pdf
Peer-review Report	16521-Peer-review(s).pdf
Scientific Misconduct Check	16521-Scientific misconduct check.pdf
Scientific Editor Work List	16521-Scientific editor work list.pdf